Skip to main content
Quest Diagnostics

Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

AAN 2025

American Academy of Neurology

San Diego, CA, Apr 5-9 , 2025

Oral presentation: Combination of Plasma Beta Amyloid 42/40 and p-tau217 in the Assessment of Alzheimer’s Disease

Authors: Racke MK, Weber DM, Louis J, Stroh M, DeSimone J, Coombes S, Vaillancourt D, Duara R, Smith G, Loewenstein D, Armstrong M, Cid Curiel R, Wang W-E,  Rayaprolu S

Specialty: Neurology

Related content

On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
Audio Podcast
Assessing for Alzheimer’s Disease with Quest Diagnostics
Audio Podcast
Alzheimer’s Disease: A New Generation of Screenings and Therapies on the Horizon
Publication
The small HDL particle hypothesis of Alzheimer's disease
Test FAQ
Quest Dementia Testing
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.